Which patients benefit from treatment?
-
Johan Hambræus
und
Fredrik Campbell
Dear Sir,
It was very interesting to read the report by Heiskanen et al. in the October issue of Scandinavian Journal of Pain [1]. We cannot but agree with the editor, Petter Borchgrevink, on the importance of assessment whether the patients benefit from the treatments or not [2]. The title for the article written by Heiskanen et al. is “Multidisciplinary pain treatment – Which patients dobenefit?”. The title by itself raises a few questions on which patients are accepted for rehabilitation at Helsinki University Central Hospital Pain Clinic. In Sweden the National Register on Pain Rehabilitation (NRPR) has registered patients assessed and treated on most of the clinics working with multimodal rehabilitation in Sweden [3,4]. One of the parameters registered are EQ-5D – a multilingual well established self-assessment tool for assessment of health related quality of life (HRQoL) [5]. According to Heiskanen et al. the 15D-instrument is comparable to the other established instruments like EQ-5D. However, while the NRPR report an average of HRQoL 0.306 at baseline while Heiskanen report values between 0.711 and 0.720, and even when they divide between responders and non-responders they report no group with less than 0.692, which is quite close to the average normal Swedish population [3,5,6]. This also put the discussion concerning “responders” and “non-responders” in a new light, especially since the responders are those with the less good HRQoL [1]. As we reported on the 14th World Congress on Pain in Milano, August 2012, we have assessed HRQoL on all patients that have come to our clinic for interventional pain management since 2008 [7].Wecould report that patients baseline HRQoL was at the same level as those registered in NRPR, 0.295–0.308. We could also report an improvement in HRQoL to 0.568 after 3 months and further to 0.626 after 12 months (p<0.0001) for those with diagnosed and treated facet joint pain. Those without facet joint pain had a less impressing improvement to 0.441 (p = 0.007) after 12 months. Since the data we have studied are anonymous we are currently unable to explore details on subgroups but we are working on the topic. Despite our concern regarding which patients are accepted for rehabilitation in Helsinki University Central Hospital Pain Clinic we would like to encourage more clinics to assess the HRQoL on their patients both at baseline and at follow up since this is the only way we will be able to compare different treatments for chronic pain in the important aspect if “...the care we provide improves the lives of those we serve. . .” [8].
DOI of refers to article: http://dx.doi.org/10.1016/j.sjpain.2012.05.073.
[1] Heiskanen T, Roine RP, Kalso E. Multidisciplinary pain treatment – which patients do benefit? Scand J Pain 2012;3:201–7.Suche in Google Scholar
[2] Borchgrevink PC, Stiles TC. What should we assess in outcome-studies to learn which patients benefit from treatments in multidisciplinary pain clinics? Scand J Pain 2012;3:199–200.Suche in Google Scholar
[3] NRSR Årsrapport 2009. 2 [Internet]; 2010. Available from: http://www.ucr.uu.se/nrs/index.php/arsrapporter/docdownload/60-arsrapport-20092Suche in Google Scholar
[4] NRSR Årsrapport 2010 [Internet]; 2011. Available from http://www.ucr.uu.se/nrs/index.php/arsrapporter/docdownload/79-arsrapport-2010Suche in Google Scholar
[5] Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001:621–35.Suche in Google Scholar
[6] Burström K, Johannesson M, Rehnberg C. Deteriorating health status in Stockholm 1998–2002: results from repeated population surveys using the EQ-5D. Qual Life Res 2007;16:1547–53.Suche in Google Scholar
[7] Campbell F, Hambraeus J, Sandström H. Interventional pain management improves quality of life. In: 14th World Congress on Pain, International Association For the Study of Pain. 2012.Suche in Google Scholar
[8] Ashburn MA, Witkin L. Integrating outcome data collection into the care of the patient with pain. Pain 2012;153:1549–50.Suche in Google Scholar
© 2012 Scandinavian Association for the Study of Pain
Artikel in diesem Heft
- Editorial comment
- A new treatment principle for neuropathic pain? Approved oncologic drugs: Epidermal growth factor receptor (EGFR) inhibitors dramatically relieve severe neuropathic pain in a case series
- Educational case report
- Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain–A case series
- Editorial comment
- Conditioned pain modulation (CPM) is not one single phenomenon – Large intra-individual differences depend on test stimulus (TS) and several other independent factors
- Original experimental
- The role of stimulation parameters on the conditioned pain modulation response
- Editorial comment
- Why we are proud to publish well-performed negative clinical studies?
- Clinical pain research
- Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal
- Editorial comment
- What really goes on behind closed doors: The need to understand communication about pain
- Observational studies
- The association between physicians’ attitudes to psychosocial aspects of low back pain and reported clinical behaviour: A complex issue
- Editorial comment
- It’s not cool to reduce the skin temperature and activate the TRPM8 ion channel after spinal injury
- Original experimental
- Activation of TRPM8 cold receptor triggers allodynia-like behavior in spinally injured rats
- Editorial comment
- Sunburn—A human inflammatory pain model for primary and secondary hyperalgesia
- Original experimental
- Central origin of pinprick hyperalgesia adjacent to an UV-B induced inflammatory skin pain model in healthy volunteers
- Editorial comment
- Validity of conclusions on treatment efficacy: Difficulties in patient recruitment and a large number of drop-outs may lead to bias
- Original experimental
- The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study
- Correspondence
- Which patients benefit from treatment?
- Correspondence
- Reply to Letter to the Editor
- Acknowledgement of Reviewers
Artikel in diesem Heft
- Editorial comment
- A new treatment principle for neuropathic pain? Approved oncologic drugs: Epidermal growth factor receptor (EGFR) inhibitors dramatically relieve severe neuropathic pain in a case series
- Educational case report
- Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain–A case series
- Editorial comment
- Conditioned pain modulation (CPM) is not one single phenomenon – Large intra-individual differences depend on test stimulus (TS) and several other independent factors
- Original experimental
- The role of stimulation parameters on the conditioned pain modulation response
- Editorial comment
- Why we are proud to publish well-performed negative clinical studies?
- Clinical pain research
- Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal
- Editorial comment
- What really goes on behind closed doors: The need to understand communication about pain
- Observational studies
- The association between physicians’ attitudes to psychosocial aspects of low back pain and reported clinical behaviour: A complex issue
- Editorial comment
- It’s not cool to reduce the skin temperature and activate the TRPM8 ion channel after spinal injury
- Original experimental
- Activation of TRPM8 cold receptor triggers allodynia-like behavior in spinally injured rats
- Editorial comment
- Sunburn—A human inflammatory pain model for primary and secondary hyperalgesia
- Original experimental
- Central origin of pinprick hyperalgesia adjacent to an UV-B induced inflammatory skin pain model in healthy volunteers
- Editorial comment
- Validity of conclusions on treatment efficacy: Difficulties in patient recruitment and a large number of drop-outs may lead to bias
- Original experimental
- The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study
- Correspondence
- Which patients benefit from treatment?
- Correspondence
- Reply to Letter to the Editor
- Acknowledgement of Reviewers
